Literature DB >> 26389634

Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker.

Eleftherios P Diamandis, Mario Plebani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26389634     DOI： 10.1515/cclm-2015-0773

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN： 1434-6621            Impact factor:   3.694


× No keyword cloud information.
  10 in total

1.  Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.

Authors:  Katherine S Yang; Hyungsoon Im; Seonki Hong; Ilaria Pergolini; Andres Fernandez Del Castillo; Rui Wang; Susan Clardy; Chen-Han Huang; Craig Pille; Soldano Ferrone; Robert Yang; Cesar M Castro; Hakho Lee; Carlos Fernandez Del Castillo; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2017-05-24       Impact factor: 17.956

2.  ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.

Authors:  Meenu Madan; Arjun Patel; Kristen Skruber; Dirk Geerts; Deborah A Altomare; Otto Phanstiel Iv
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

3.  A signal-amplifiable biochip quantifies extracellular vesicle-associated RNAs for early cancer detection.

Authors:  Jiaming Hu; Yan Sheng; Kwang Joo Kwak; Junfeng Shi; Bohao Yu; L James Lee
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

4.  Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.

Authors:  Wenli Qiu; Rong Chen; Xiao Chen; Huifeng Zhang; Lina Song; Wenjing Cui; Jingjing Zhang; Dandan Ye; Yifen Zhang; Zhongqiu Wang
Journal:  Int J Nanomedicine       Date:  2018-10-24

5.  ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.

Authors:  Hye-Su Shin; Sang Baek Jung; Sungho Park; Pooja Dua; Dong Ki Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-12       Impact factor: 6.698

6.  Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.

Authors:  Dmitry Polikarpov; Liuen Liang; Andrew Care; Anwar Sunna; Douglas Campbell; Bradley Walsh; Irina Balalaeva; Andrei Zvyagin; David Gillatt; Evgenii Guryev
Journal:  Biomolecules       Date:  2019-12-03

7.  Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer.

Authors:  Yu Mu; Dezhi Wang; Liangyu Bie; Suxia Luo; Xiaoqian Mu; Yanqiu Zhao
Journal:  Aging (Albany NY)       Date:  2020-10-09       Impact factor: 5.682

Review 8.  Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer.

Authors:  Kazufumi Honda; Sudhir Srivastava
Journal:  Biomark Med       Date:  2016-09-27       Impact factor: 2.851

9.  Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.

Authors:  Adam E Frampton; Mireia Mato Prado; Elena López-Jiménez; Ana Belen Fajardo-Puerta; Zaynab A R Jawad; Phillip Lawton; Elisa Giovannetti; Nagy A Habib; Leandro Castellano; Justin Stebbing; Jonathan Krell; Long R Jiao
Journal:  Oncotarget       Date:  2018-04-10

Review 10.  The function and clinical application of extracellular vesicles in innate immune regulation.

Authors:  Xiaoxue Zhou; Feng Xie; Lin Wang; Long Zhang; Suping Zhang; Meiyu Fang; Fangfang Zhou
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.